Replies to post #360246 on Anavex Life Sciences Corp (AVXL)

[xodcode]

Thanks nidan7500!

Yet another notch in the AVXL belt, probably worth two notches!

[boi568]

Why is this application not patently obvious (pun intended)? Doesn't every doctor adjust medication?

[falconer66a]

Extremely important new technology.

This is a patent [not an application] for the (a) diagnostic-treatment process or method which will be used to examine, measure, diagnose, analyze, treat, then reanalyze pt. changes and to iteratively resolve pts. CNS disease(s) /disorders and symptoms.

Nidan, well-noted. Thanks for posting this.

The Anavex sigma-1 technology continues to emerge; entirely new to medicine. Here, in this new patent, it offers entirely new processes to diagnose and treat central nervous system diseases.

In the 1940s antibiotics changed medicine. In the 2020s, it will be Anavex drugs and processes. The patent office attorneys certainly scrutinized the patent application. They approved it. All new stuff; will change things remarkably.

[jmvho]

nidan - You are truly en fuego this week !!

Three Modelo Especials for you tonight.

jmvho

[awm0912]

That is a very uplifting text you wrote. Thanks that made my day…

[Jonjones325]

Is the general process patented or just the process as it relates to 2-73?

Not sure if the general process can be patented. Thanks

[gbrown6332]

Thanks... Intuitive insights, uplifting post.

G.B.

[nidan7500]

An observation on AVXL latest patent APP-REV 1...IMO, this may serve as NDA supporting evidence.

I should have also mentioned earlier that this patent app may also serve as A/the method Dr.M. has chosen to "Validate the S1R MOA". It is extremely visionary-clever of him if that is his mission w/this patent.

What is FDA process validation?
Image result for fda requirements for validation of a process
The FDA defines process validation as, “…the collection and evaluation of data, from the process design stage through commercial production, which establishes scientific evidence that a process is capable of consistently delivering quality product”.Sep 1, 2020

https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220220142968%22.PGNR.&OS=DN/20220142968&RS=DN/20220142968

This is a patent for the (a) diagnostic-treatment process or method which will be used to examine, measure, diagnose, analyze, treat, then reanalyze pt. changes and to iteratively resolve pts. CNS disease(s) /disorders and symptoms.
This process will likely use tool suites(AI??) and methods certain to evolve. This is the opposite of the FDA DART BOARD Methods used for decades w/no clear benefit.

This is why Dr.M. knows he got this. This is absolute genius, brilliant stuff. He is applying scientific methods to diagnose and resolve CNS diseases and disorders. It is applicable to all CNS -previously untreatable-diseases. AVXL will entirely own the effective solution through treatment to all CNS diseases WW. BRILLIANT.

The only other such well known case where a PROCESS was patented that I am aware of is the PLANAR process (1960). This patent and royalties applied to every semiconductor device (diode, transistor, Integrated ckt. of every type produced since 1960).

Wait till WS figures that out. Trouble is we will see a lot of liars and lawyers .

WE REALLY GOT THIS[/b]...wait till they all figure this one out. BOOM.

[jimmy_mcyoloswag]

Another great example to better leave it to the natural scientists to fix the medical field.. :P

[boi568]

My thoughts on the most recent patent application . . ..

I think this new neurodevelopmental patent application serves two purposes. First, it redefines the medical use of 2-73 on the basis of symptoms and biomarkers, rather than disease names. Second, it restarts the full patent protection clock on the medical use of 2-73 for this category of diseases. (We should expect a similar patent app coming for the neurodegenerative diseases in the not too distant future.). Both prongs are important.

The first prong is not as obvious as the second. Aside from demonstrating Anavex's commitment to a platform-based pharmaceutical, it also indicates that the company's research shows the best treatment regime correlates according to symptom and biomarker, rather than by disease diagnosis. (Shades of Mayomobile's predictive matrix are appearing to me.) Put another way, I think this means that the company has found the dose-response curve to track symptoms and biomarkers better than diseases. This is consistent with the Anavex position that it has an upstream, platform-based solution acting above specific indications.

Take Rett, for example, where some here have raised dose-response concerns. Rett patients are not all alike, either in the specific underlying disease causes or in the combinations of their symptoms. This from a fairly recent study in Norway, entitled "Rett Syndrome: A more heterogenous group than previously thought?": "91 individuals were included; 72 had classic RTT, 12 atypical RTT and seven did not fulfill the diagnostic criteria. Mutations in MECP2were found in 77 individuals. In addition, mutations in SMC1A, SYNGAP1, SCN1A, CDKL5, FOXG1and Chromosome 13q were found. Comparison of individuals with RTT with and without MECP2mutations revealed significant differences in early development, loss of hand use and language, intense eye gaze and the presence of early onset epilepsy."

If AVATAR and EXCELLENCE dose response curves weaken or fail according to a Rett Syndrome diagnosis among a heterogenous group of patients, they may strengthen or appear if the problem is redefined, as in this patent application, as a variety of neurodevelopmental symptoms and associated biomarkers, each responding to somewhat different dosages of 2-73. Will Anavex have sufficiennt data to support this kind of Rett analysis? I think that's the direction they intend to go, if possible.

Second, if Anavex is preparing the scientific methods for medical treatment for neurodevelopmental disease through this patent, anyone else selling the pharmaceutical will inevitably fall within its scope of the 2-73 neurodevelopmental medical manual. Every year of patent protection is golden.

Hello, 2040's.

[Schmiggins]

Serendipitously just discovered this great post about our diagnostics patent. It ties in with what we are discussing re: Partex and the complexities to come.